HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $52

Benzinga Newsdesk www.benzinga.com Positive 81.6%

Neg 0% Neu 0% Pos 81.6%

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $37 to $52.